Lamivudine 100 Savi treatment for hepatitis (3 blisters x 10 tablets)

Dosage form Box of 3 blisters x 10 tablets
Specifications Lamivudine

Ingredient

Composition information	Content
Lamivudine	100mg

Uses

indications

lamivudin drugs are indicated in the following cases:

Treatment of chronic hepatitis B and there is evidence to copy of the hepatitis B virus (HBV) with the following conditions:

Alanin Aminotransferase (ALT) has increased 2 times compared to normal.

Progressive viral hepatitis.

Pharmacology

lamivudin is an anti -Retrovirus synthetic drug, belonging to the Dideoxibeosid group inhibiting the reverse code enzyme of the virus. For lamivudine effect, the phosphoryl cells must be used. This metabolic substance has a similar structure to Deoxyctidin Triphosphate, which is a natural substrate for the enzyme transcription. The drug has a competitive activity with natural deoxyctidin triphosphate to merge the virus's DNA because the enzyme is transcribed inverted, causing the early end of the virus's DNA synthesis. Lamivudin has very low toxicity for cells.

lamivudin has the activity of HIV type 1 and 2 HIV (HIV - 1, 2), and also has the effect of inhibiting the hepatitis B virus in chronic patients. Despite being well tolerated, but not used lamivudin is alone because it is easy to produce resistance. This resistance due to an enzyme mutation transcription, reducing sensitivity more than 100 times and loses antiviral effects on patients. Lamivudin and zidovudin combination therapy in patients who have not been previously treated by a decrease in viral density in plasma, lasting for more than 1 year, despite the mutant of reverse transcription enzymes.

In Retrovirus anti -Retrovirus therapy, selective drugs are similar to nucleosides, Retrovirus resistance therapy also increases survival time in patients with CD4 cells under 500/ 1mm2. This therapy is also used for patients with HIV density of over 30,000/ml of plasma, regardless of CD4 cells, because HIV density is a prognosis factor for the progression of the disease. Higher viral density leads to faster CD4 cell reduction. The goal of treatment is to achieve HIV density at an inexplicable level. The current standard therapy consists of 2 similar drugs Nucleosid resistant to Retrovirus, along with a protease inhibitors.

The patient is not effective (tripled with viral density, or a decrease in the number of CD4 cells or progresses to AIDS disease) to turn to another combination of antiviral drugs. Must choose to combine new drugs so that the risk of diagonal resistance with minimum dose drugs. When the old therapy does not have the effect of adding new medicine, the principle is to add not only one medicine but combine 2 new drugs.

pharmacokinetics

absorption:

After drinking, Lamivudin absorbs rapidly with bioavailability about 80%. The ratio is attached to low plasma proteins (

Metabolism:

5 - 6% of the drug is converted into Trans - Sulfoxyd.

Era:

The average plasma sale time is 2.5 hours and about 70% of the dosage is eliminated without changing in the urine. The sale time of lamivudin triphosphate in the cell is prolonged, on average over 10 hours in lymphocytes in peripheral blood. The total clearance is 0.37 ± 0.05 liters/gid/kg.

Before taking Lamivudine 100 Savi treatment for hepatitis (3 blisters x 10 tablets)

How to use

Take oral use.

Dosage

suggested dose is 100 mg/time/day.

Adults: 1 tablet/time, drink 1 time.

Children over 12 years: 3 mg/kg/day (maximum 100 mg/day) corresponds to a single dose of 100 mg/day in adults.

Consider stopping lamivudin in the case:

Reverse serum price for HBeAg and/or HBsAg confirmed in patients with normal immune system.

Pregnant female patients during treatment.

Patients with signs of lamivudin intolerance during treatment.

Renal failure: Dosage for patients with creatinine clearance

Note: The above dose is for reference only. Specific dosage depends on the condition and level of progression of the disease. For a suitable dose, you need to consult a doctor or medical specialist.What do

do when overdose? There is no antidote. It is unknown whether lamivudin is excluded by the abdominal separation or hemorrhage.

What to do when forgetting 1 dose?

Not recorded.

Side Effects

When using lamivudin, you may experience unwanted effects (ADR).

Common, ADR> 1/100

headache, insomnia, discomfort, fatigue, pain, dizziness, depression, fever, chilling, nausea, vomiting, diarrhea, anorexia, abdominal pain, indigestion, amylase increased, peripheral neuropathy, abnormalities, muscle pain, joint pain, rash, signs and symptoms in the nose, neutropenia, anemia, AST, ALT.

rarely

Pancreatitis, thrombocytopenia, hyperkemin blood.

Notify the doctor with unwanted effects when using the drug.

Instructions on how to handle ADR

When experiencing side effects of the drug, it is necessary to stop using and notify the doctor or go to the nearest medical facility for timely treatment.

Warnings

Before using the drug you need to read the instructions carefully and refer to the information below.

Contraindicated

Lamivudine drugs contraindicated in the following cases:

Hypersensitivity to lamivudin or any ingredients of the drug.

Severe renal impairment.

Be cautious when using

After stopping lamivudin, patients may have chronic virus recurrence, which can cause more serious consequences in patients with liver disease. Clinically monitoring and evaluation of liver functional serum tests (ALT and Bilirubin concentrations) for at least 4 months to find evidence of recurrent viral hepatitis. For people with symptoms of recurrent hepatitis after treatment, do not start treating with lamivudine because of the very low efficiency.

To treat patients with HIV infection simultaneously, the lamivudin dose should be maintained 20 mg twice a day, using lamivudin individually or in combination with zidovudin 300 mg.

Should be cautious for pregnant and lactating women.

LAMIVUDIN treatment has not been shown to reduce the risk of hepatitis B virus transmission to others, thus applying appropriate prevention measures to these patients.

The ability to drive and operate machinery

The drug does not affect the ability to drive and operate machinery.

Pregnancy

can use lamivudin for pregnant women, especially when the sewing mechanical protects from infection to the fetus. In case of using lamivudin combined (lamivudin and zidovudin), avoiding for pregnant women.

The period of breastfeeding

Whether it is not known whether lamivudin is excreted in milk or not, there is likely the unwanted effects caused by lamivudin in young children. There is also a high risk of HIV infection due to breastfeeding. Instructions for HIV -infected mothers should not breastfeed.

Drug interaction

lamivudin is eliminated by the kidneys by the organic cation activity. The drugs are excreted in this road, especially cases with low treatment index, which may be interacted with lamivudin.

Zidovudine concentration in plasma increases significantly (about 39%) when used in combination with lamivudin.

trimethoprim/sulfamethoxazol increases the bioavailability of lamivudin (44%) reflected in the measurement of the area under the concentration - time curve (AUC) and reduces the renal clearance (30%).

The lamivudine absorption is slowed down and the plasma peak concentration is lower than 40% when the patient takes the drug when full compared to when taking the drug when hungry.

Storage

In a cool dry place, avoid light, at temperatures below 30ºC.

Other drugs

Disclaimer

Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.

The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.